Abstract
Recent studies on gene, inhalation and dermal toxicity of few-layer graphene have revealed much lower health risk than expected. This could pave the way for graphene as a young member of the nanocarbons family to become the “heir presumptive” to the long-reigning carbon black.
Highlights
Recent studies on gene, inhalation and dermal toxicity of few-layer graphene have revealed much lower health risk than expected
There has always been a shadow of health and safety concerns for use of nanocarbons in real life
The toxicology of mono-layer graphene commonly made by chemical vapor deposition (CVD), graphene oxide, and reduced graphene oxide is beyond the scope of this short communication
Summary
Carbon in nanoform has been one of the hottest research and development topics in the past two decades. Given other commercialization barriers [15] such as the costs associated with market and application development, product certification costs, and revenue uncertainty, many graphene producers have had no choice but to postpone such studies or rely mostly on existing studies for graphene’s so-called “analogues” such as carbon nanotubes or graphite. Such approaches often cause more uncertainty and leave the regulators with even more doubts. The toxicology of mono-layer graphene commonly made by chemical vapor deposition (CVD), graphene oxide, and reduced graphene oxide is beyond the scope of this short communication
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
